| 7592466 |
Ureas having antiangiogenic activity |
Michael Bradley, Daryl Sauer |
2009-09-22 |
$133,275,000 |
| 7432245 |
Pharmaceutical formulation comprising a peptide angiogenesis inhibitor |
Bryan K. Erickson, Jack Henkin, Luk-Chiu Li, Fanfeng Ma, Friedrich Richter +3 more |
2008-10-07 |
$110,217,000 |
| 7169888 |
Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity |
Michael Bradley |
2007-01-30 |
$37,280,000 |
| 7122625 |
Hexa-, hepta-, and octapeptides having antiangiogenic activity |
Michael Bradley |
2006-10-17 |
$164,996,000 |
| 7067490 |
Hepta-, Octa-and nonapeptides having antiangiogenic activity |
Michael Bradley |
2006-06-27 |
$96,655,000 |
| 7037897 |
TRI-, TETRA-, and penta-peptides having antiangiogenic activity |
Michael Bradley |
2006-05-02 |
$56,784,000 |
| 7001984 |
Di-, tri-, and tetra-peptides having antiangiogenic activity |
Michael Bradley |
2006-02-21 |
$42,599,000 |
| 6777535 |
N-alkylated peptides having antiangiogenic activity |
Jack Henkin, Douglas M. Kalvin, Michael Bradley |
2004-08-17 |
$57,458,000 |
| 6774211 |
Peptide antiangiogenic drugs |
Jack Henkin, Michael Bradley, Douglas M. Kalvin, Andrew J. Schneider |
2004-08-10 |
$59,696,000 |
| 6753408 |
Peptides having antiangiogenic activity |
Jack Henkin, Michael Bradley, Douglas M. Kalvin, Andrew J. Schneider |
2004-06-22 |
|
| 6716963 |
Peptide antiangiogenic drugs |
Jack Henkin, Michael Bradley, Douglas M. Kalvin, Andrew J. Schneider |
2004-04-06 |
$72,847,000 |
| 6387885 |
3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists |
Christopher R. Dalton, Milan Bruncko, Michele A. Kaminski, Lisa M. Frey, Daryl Sauer |
2002-05-14 |
$75,315,000 |
| 6297354 |
Pentapeptide LHRH antagonists |
Wesley J. Dwight, Jonathan Greer |
2001-10-02 |
$137,144,000 |
| 6191115 |
C-terminus modified heptapeptide LHRH analogs |
Wesley J. Dwight, Charles J. Nichols, Jonathan Greer |
2001-02-20 |
$224,580,000 |
| 6020521 |
Macrolide LHRH antagonists |
John T. Randolph, Daryl Sauer, Philip Waid, Charles J. Nichols, Nicholas A. Mort +2 more |
2000-02-01 |
$89,588,000 |
| 5981521 |
Tetrahydroisoquinoline derivatives as LHRH antagonists |
Wesley J. Dwight, Bradley W. Crawford, Rolf E. Swenson, Milan Bruncko, Michele A. Kaminski +3 more |
1999-11-09 |
$58,994,000 |
| 5972898 |
3',3-N-bis-substituted macrolide LHRH antagonists |
Daryl Sauer, John T. Randolph, Nicholas A. Mort, Christopher R. Dalton, Milan Bruncko +4 more |
1999-10-26 |
$74,678,000 |
| 5955440 |
Macrolide LHRH antagonists |
Daryl Sauer, John T. Randolph, Nicholas A. Mort, Christopher R. Dalton, Milan Bruncko +4 more |
1999-09-21 |
$61,755,000 |
| 5698522 |
6-position modified decapeptide LHRH antagonists |
Timothy D. Fitzpatrick, Rolf E. Swenson, Charles J. Nichols, Nicholas A. Mort, Jonathan Greer |
1997-12-16 |
$31,782,000 |
| 5516759 |
LHRH antagonists having lactam groups at the N-terminus |
Rolf E. Swenson, Nicholas A. Mort |
1996-05-14 |
|
| 5516647 |
Compounds useful as alkaline phosphatase inhibitors and therapeutic agents |
Mazhar Husain, Dominique P. Bridon, Mark G. Bures, James D. Ratajczyk, Christopher Bieniarz |
1996-05-14 |
$22,194,000 |
| 5508383 |
Cyclic peptide LHRH antagonists |
Daryl Sauer |
1996-04-16 |
|
| 5502035 |
N-terminus modified analogs of LHRH |
Timothy D. Fitzpatrick, Rolf E. Swenson, Charles J. Nichols, Nicholas A. Mort |
1996-03-26 |
|
| 5491217 |
LHRH antagonists having modified aminoacyl residues at positions 5 and 6 |
Jonathan Greer, Rolf E. Swenson, Daryl Sauer |
1996-02-13 |
|
| 5432263 |
Process for producing peptides with side chains containing imidazolinylamino, tetrahydropyrimidinylamino, or alkylguanidinyl groups |
Rolf E. Swenson, Timothy D. Fitzpatrick |
1995-07-11 |
$55,427,000 |
